"
Team:SupBiotech-Paris/Conclusion1Fr
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
Enguerrand (Talk | contribs) |
||
| Line 1: | Line 1: | ||
{{Template:Supbiotechcss.css}} | {{Template:Supbiotechcss.css}} | ||
{{Template:SupbiotechparisFr}} | {{Template:SupbiotechparisFr}} | ||
| - | |||
| - | |||
| - | |||
| - | |||
| + | [[Team:SupBiotech-Paris/Conclusion1Fr#drapeau|Haut de page]] | ||
<html> | <html> | ||
Revision as of 10:52, 17 October 2009
Projet
Introduction Thérapies actuelles Thérapies géniques Le DVS Concept Vecteur Tissulaire Vecteur Cellulaire Plasmide thérapeutique Conclusion Mise en application Ciblage Tissulaire Action antitumorale Modeling du traitement Conclusion
Ressources
BioBricks Matériel & Méthode Bibliographie
Ethique & sûreté
